So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.Utsumi, Kouichi; Yasuda, Fumihiko; Watanabe, Yoko; Higo, Seiichiro; Hirama, Akio; Fujita, Emiko; Ueda, Kae; Mii, Akiko; Kaneko, Tomohiro; Mishina, Masahiro; Iino, Yasuhiko; Katayama, Yasuo researched the compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride( cas:89396-94-1 ).Recommanded Product: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride.They published the article 《Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients》 about this compound( cas:89396-94-1 ) in Clinica Chimica Acta. Keywords: olmesartan medoxomil imidapril hydrochloride adiponectin Pselectin diabetic nephropathy antioxidant. We’ll tell you more about this compound (cas:89396-94-1).
The effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of 20 diabetic nephropathy patients were explored. The administration of olmesartan and imidapril was safe and did not produce any adverse effects. Adiponectin significantly increased after 12 wk of olmesartan administration. However, subsequently, there was no further increase in the adiponectin level despite combination therapy with imidapril for 12 wk after administration. However, this parameter significantly decreased after 12-wk combination therapy with imidapril. The MDA-LDL level significantly reduced after 12 wk of olmesartan administration. There was no further decrease after 12-wk combination therapy with imidapril. Levels of P-selectin were not significantly decreased for 12 wk olmesartan administration but were significantly decreased after 12-wk combination therapy with imidapril. Data generally indicates that combined therapy with ACEI and ARB has beneficial effects on long-term renal outcome.
After consulting a lot of data, we found that this compound(89396-94-1)Recommanded Product: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride can be used in many types of reactions. And in most cases, this compound has more advantages.
Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”